AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines

The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).

Inclusion Criteria:

-Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (at least 10 weeks after study intervention).

Exclusion Criteria:

• Known immunization or hypersensitivity to any botulinum neurotoxin serotype
• Any medical condition that may put the participant at increased risk with exposure to AGN-151586, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
• Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or the inability to substantially lessen facial lines even by physically spreading them apart, as determined by the investigator
• Any brow or eyelid ptosis, as determined by the investigator
• Infection or skin disorder at the injection sites
• History of facial nerve palsy
• Any uncontrolled systemic disease
• Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study intervention)
• Anticipated need for surgery or overnight hospitalization during the study
• Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery)
• Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation
• Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Screening